The Administrative Core (AC) serves as the central coordinating center that manages and integrates the multiple program activities carried out at the ADCS and co-located facilities, and is necessary to maintain smooth operation of this complex grant program. Because the AC activities integrate with the activities of each of the other ADCS cores and committees it results in a multi-faceted approach that lends itself to communication and information sharing among all cores. The primary objective of the AC is to provide overall direction and oversight to the ADCS by working closely with its various cores and committees to accomplish program goals. The ADCS is a large, complex organization, with over 100 members at UCSD, 8 cores, 35 primary performance sites, dozens of additional sites, multiple ongoing trials, collaborations with multiple companies, and contracts with many vendors. It is primarily an academic organization, but performs all of the activities required by multicenter trials, with an in-house data management system, biostatistics, clinical operations, regulatory oversight, medical and safety management, and onsite and remote clinical monitoring. Smooth operation requires, in addition to experience and expertise, efficient and effective management, standard operating procedures and quality assurance programs, and effective communications. The standing committees, which exist throughout the grant period, contribute to all grant activities. The Committees budgeted within the Administrative Core are the Internal Ethics Committee, the Clinical Dementia Rating Scale Committee, and the Instrument Committee with its five subcommittees.

Public Health Relevance

There is no greater health care need than the development of effective therapy for AD. With aging baby-boomers now at the age of risk for AD, the epidemic will accelerate. The ADCS maintains an optimized infrastructure to support its trials, as well as trials and longitudinal studies funded by other grants, and to facilitate sharing of data, specimens and methods.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AG010483-23
Application #
8601637
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
23
Fiscal Year
2014
Total Cost
$1,614,167
Indirect Cost
$273,586
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Amyloid and APOE ?4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82:1760-7
Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71:1379-85
Rafii, Michael S; Taylor, Curtis S; Kim, Hyun T et al. (2014) Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen 29:159-65
Whitehouse, Peter J (2014) The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. Biochem Pharmacol 88:677-81
Burstein, Aaron H; Grimes, Imogene; Galasko, Douglas R et al. (2014) Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 14:12
Donohue, Michael C; Jacqmin-Gadda, Hélène; Le Goff, Mélanie et al. (2014) Estimating long-term multivariate progression from short-term data. Alzheimers Dement 10:S400-10
Samieri, Cécilia; Proust-Lima, Cécile; M Glymour, Maria et al. (2014) Subjective cognitive concerns, episodic memory, and the APOE ?4 allele. Alzheimers Dement 10:752-759.e1
Galasko, Douglas; Bell, Joanne; Mancuso, Jessica Y et al. (2014) Clinical trial of an inhibitor of RAGE-A? interactions in Alzheimer disease. Neurology 82:1536-42
Sperling, Reisa A; Rentz, Dorene M; Johnson, Keith A et al. (2014) The A4 study: stopping AD before symptoms begin? Sci Transl Med 6:228fs13
Papay, Kimberly; Xie, Sharon X; Stern, Matthew et al. (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83:826-33

Showing the most recent 10 out of 14 publications